Coercion and Undue Inducement in Recruitment

Alan Wertheimer, Ph.D.
Professor Emeritus of Political Science
University of Vermont

Department of Bioethics
National Institutes of Health

October 2014
The basic problem

• Research requires subjects
• In some cases, recruitment is easy
• But in some cases, recruitment is difficult
• Participation may be risky, inconvenient, painful
• Altruism is limited
• Subject accrual is often slow. Many studies do not complete. More studies are not proposed.
The basic problem

• “Lack of study volunteers hobbles cancer fight” (NYT Headline, August, 2009)

• 3% of adult cancer patients participate

• More than 1/5 trials sponsored by NIC failed to enroll a single subject and only half reached minimum needed for a meaningful result
Recruitment as Collective Action

Problem

• It is in everyone’s interest that research be conducted
• It is sometimes in an individual’s interest NOT to participate
• In some areas of social life we use government coercion to solve a collective action problem
• Not in research
The basic problem

• Consent is required (except when it’s not)
• We may use incentives to get people to participate
• Not a new phenomenon
Walter Reed

- Yellow fever studies in Cuba (1900).
- Intentional exposure.
- Paid $100 in gold.
- $100 bonus for successful infection.
- Payable to family in the event of death.

http://etext.lib.virginia.edu/healthsci/reed/commission.html#vo
Payment Today

• “Make $1,000's... Get paid hundreds weekly in additional cash income, part-time, while relaxing in a million-dollar, get paid research study... Yes, there are thousands of cash paying studies and even free medical care available!”

• “Get paid up to $1,000 weekly for safe sex research?”

http://www.rxgetpaid.com
UVM Will Make People Sick to Test an Experimental Cholera Vaccine

- Placebo controlled challenge study
- $3,000
- Get vaccine
- Return 10 or 90 days later
- Drink solution containing cholera pathogen
- 12 days in hospital under around-the-clock supervision
- Oral or IV rehydration if necessary
Other Incentives

- Free treatment (or chance of treatment)
- Free medical examinations
- Experimental Treatment
- Post-trial treatment
- Ancillary Care or Incidental Findings
Payment in the U.S.

• Payments made in Phase I, II, III
• At least 23% of protocols at academic institutions paid subjects.
  – Few have any method of tracking paid studies
• Frequency of payment higher at independent IRBs and pharmaceutical companies.

Why do we pay research subjects?

- Reimbursement
- Compensation for time and burdens
- Compensation for risk
- Avoid exploitation
- Incentive for recruitment
- Some reasons are more accepted than others
## Results: Reasons for paying and views about paying healthy and patient volunteers

<table>
<thead>
<tr>
<th>% who agree or strongly agree that it is acceptable to...</th>
<th>Healthy Volunteer</th>
<th>Patient-subjects with no prospect of benefit</th>
<th>Patient-subjects with a prospect of benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Offer Money</td>
<td>86.8%</td>
<td>78.7%</td>
<td>71.1%</td>
</tr>
<tr>
<td>Reimburse for expenses</td>
<td>97.9%</td>
<td>95.4%</td>
<td>92.8%</td>
</tr>
<tr>
<td>Compensate for time, effort, inconvenience</td>
<td>94.5%</td>
<td>90.7%</td>
<td>86.2%</td>
</tr>
<tr>
<td>Offer money as an incentive</td>
<td>58.3%</td>
<td>56.2%</td>
<td>50.2%</td>
</tr>
<tr>
<td>Offer money to compensate for risk</td>
<td>36.4%</td>
<td>36.9%</td>
<td>34.6%</td>
</tr>
</tbody>
</table>

The State of Payment in the U.S.

• Payment is very common.
• All types of subjects are paid.
• Payment is erratic with little institutional guidance or consistency.
• Payment is generally modest.
• Significant disagreement over payment as incentive or for risk.
• Lots of worrying
Results: concern about payment

- Payment in any amount
- Token payment
- Substantial payment

Legend:
- Very concerned
- Moderately concerned
- Somewhat concerned
- Little concern
What are the worries?

• Consent
  – Coercion
  – Undue Influence

• Other
  – Commodification
  – Trust in research enterprise
  – Scientific
    • Conceal information
    • Feign illness (psychiatric research)
    • Reporting adverse events
    • Skewing population
Anecdotal Evidence

• Anecdotal evidence suggests that many IRB members think that payment or offers of medical care do or can coerce or constitute undue influence

• Our study showed that this hypothesis is correct
What’s the problem?

• To the extent that IRB members’ attitudes regarding payment are ethically sound, they appropriately influence payment practices.

• Studies should not be approved if participants’ consent is likely to be compromised by coercion or undue influence.

• If IRB members’ concerns are based on conceptual or ethical misconceptions, unnecessary limits may be placed on payments to research participants and impede valuable research without ethical cause.
Consequences of the worries

• Fact that payments are frequently made does not show that worries make no difference (speed limits)
• Not how many protocols are disapproved
• But how many protocols that would otherwise pass muster are not proposed or even considered?
• Does research progress more slowly?
Our Thesis

• Many of the prevalent concerns about payment are largely misguided.
• Payment never coerces.
• Payment raises ethical concerns with respect to consent only when it unduly influences participants by distorting their perception of research risks and benefits.
• In the absence of evidence that such distortions occur, IRBs should be reluctant to conclude that offers of payment undermine the validity of consent.

Regulatory Statements
The Common Rule

“An investigator shall seek such consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence.”

45 CFR 46, 116
“The IRB should review both the amount of payment and the proposed method and timing of disbursement to assure that neither are coercive or present undue influence.” FDA Information Sheets, 1998
“... the IRB should review both the amount of payment and the proposed method of disbursement to assure that neither entails problems of coercion or undue influence. Such problems might occur, for example, if the entire payment were to be contingent upon completion of the study or if the payment were unusually large. Payments should reflect the degree of risk, inconvenience, or discomfort associated with participation.“

How do IRB members understand coercion?
## Results: Respondent views on coercion and undue influence

<table>
<thead>
<tr>
<th>% of respondents who agreed or strongly agreed that <em>if</em> the research participants …</th>
<th><em>Then</em> …it is coercion</th>
<th><em>Then</em> …it is undue influence</th>
</tr>
</thead>
<tbody>
<tr>
<td>…are threatened with harm</td>
<td>91.2%</td>
<td>-----</td>
</tr>
<tr>
<td>…will participate with payment when otherwise they would not</td>
<td>64.8%</td>
<td>81.0%</td>
</tr>
<tr>
<td>…feel they have no reasonable alternative but to participate because of payment</td>
<td>81.6%</td>
<td>79.2%</td>
</tr>
<tr>
<td>…ability to accurately perceive risks and benefits is distorted when offered payment</td>
<td>---</td>
<td>98.2%</td>
</tr>
</tbody>
</table>
Coercion

• Some people think that offers of payment are coercive if and when they get someone to agree to participate in research when they would otherwise not.

• There are numerous ways of motivating people to do things that they would otherwise not do
  – A persuades B to give blood or go to a movie or invest in a mutual fund
  – A offers the teenager next door $20 to mow his lawn.
  – As a general proposition, offers do not coerce.
  – Offers can be indecent and immoral but they do not coerce
Coercion

• A coerces B to do consent to do X in a way that invalidates B’s consent only if A proposes to harm B if B does not consent to do X

• The *Belmont Report*: “Coercion occurs when an overt threat of harm is intentionally presented by one person to another in order to obtain compliance.”

• Examples
  – Gunman case
  – Extortion
  – The Godfather’s Offer
Coercion

• Threats v. offers
• Threats reduce options
• Offers enhance options
Coercion

• Some people think that people are coerced to participate in research when they have no reasonable alternative but to consent to participate.

• Attractive but mistaken view
Coercion

• We do *not* say that a patient who agrees to surgery or chemotherapy because the only alternative is death has been coerced to consent or that her consent to treatment is involuntary or invalid.

• We do *not* describe people as coerced if they take an unpleasant job in order to provide for their families.

• They are not coerced if they agree to participate in a cholera vaccine trial for $3000.
Coercion by Illness
The Jesse Gelsinger Case

• Jesse Gelsinger, 18, had a mild form of a rare metabolic disorder
• In 1999, enrolled in Phase I gene-therapy trial at U Penn.
• On Sept 13, he was injected with a weakened cold virus carrying corrective genes. Four days later he died from an immune reaction to the virus vector
Coercion By Illness?
The Jesse Gelsinger Case

• Gene therapy not designed for treatment of people like Jesse who had mild form of disease, but for neonates with a more severe and almost always fatal form.

• Researchers had planned to test treatment on terminal neonates

• They were persuaded to test it on adults because adults could give consent
Coercion By Illness?
The Jesse Gelsinger Case

• Arthur Caplan: The parents of dying infants are incapable of giving informed consent – “They are coerced by the disease of the child”

• Issue is not merely semantic

• Issue is the regulatory and decisional effects of describing or labeling payment as coercive
Coercion is Rare in Research

• Cases where retribution is conceivable.
  – A physician may threaten to abandon a patient who refuses to participate in a study.
  – Explicit v. tacit threats

• Perceived coercion is possible.
  – Patient participates in a study run by his PCP because the patient mistakenly fears his care is contingent on participation.
A clear answer?

• “How large a payment constitutes “undue influence” or a coercive offer to participate in research is a question . . . for which no clear answer is forthcoming.” (Ruth Macklin)

• A clear answer is forthcoming: offers of payment do not coerce

• Stop worrying about coercion
Undue Influence

• When do offers of payment constitute undue influence?

• A different question
Inducement

• Inducements are offers that get people to do things they would not otherwise do.

• Inducements are typically unproblematic
  – Jobs
  – Market transactions
  – Parenting
Undue Inducement

“...monetary inducements may be undue if they alter patients’ decision-making processes such that they do not appropriately consider the risks of participating.” Halpern, et. al. Arch. Intern Med. 2004
Undue Inducement

“An offer one could not refuse is essentially coercive (or "undue"). Undue inducements may be troublesome because . . . . offers that are too attractive may blind prospective subjects to the risks or impair their ability to exercise proper judgment . . . ”

The Core of Undue Inducements

• Inducements are problematic when they distort the target’s decision-making.

• Tunnel Vision
  – Focusing on gain
  – Ignoring cost

• Myopia
  – Overweighting short term gains
  – Underweighting long term costs
  – Hyperbolic discounting
Undue Influence

• “Monetary need may cloud a patient’s decision-making, exposing the individual to a greater level of risk than he or she might otherwise accept” (David Rothman)

• Half right
Risky Jobs

• Coal mining
• Logging
• Commercial fishing
• Structural Steel
• Fire fighters
• Soldiers
• Is research different?
How Much Should Subjects Receive?

- Reimbursement
- Inconvenience
- Time
- Risk
- Market: Whatever it takes
Payment and Risk/Benefit

• In assessing whether risks to subjects are reasonable in relation to benefits to subjects or to others . . .

• Should payment be regarded as a benefit that offsets risk?

• Standard View: NO
Conclusion

• Does payment or paying more compromise the voluntariness of consent? It might, but probably less than is often thought.